BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1877393)

  • 21. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY; Mistry P; Kelland LR; Abel G; Harrap KR
    Br J Cancer; 1992 Dec; 66(6):1109-15. PubMed ID: 1457352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M; Siracky J; Kelland LR; Harrap KR
    Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
    Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
    Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ; Barnard CF; Kelland LR; Harrap KR
    Int J Cancer; 1994 Oct; 59(1):65-70. PubMed ID: 7927906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines.
    Anderson WK; Kasliwal R; Houston DM; Wang YS; Narayanan VL; Haugwitz RD; Plowman J
    J Med Chem; 1995 Sep; 38(19):3789-97. PubMed ID: 7562909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
    Sova P; Mistr A; Kroutil A; Zak F; Pouckova P; Zadinova M
    Anticancer Drugs; 2005 Jul; 16(6):653-7. PubMed ID: 15930894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
    Kido Y; Khokhar AR; Siddik ZH
    Anticancer Drugs; 1993 Apr; 4(2):251-8. PubMed ID: 8490203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
    Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
    Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II).
    Wilkoff LJ; Dulmadge EA; Trader MW; Harrison SD; Griswold DP
    Cancer Chemother Pharmacol; 1987; 20(2):96-100. PubMed ID: 3664938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
    McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
    Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Nicolson MC; Orr RM; O'Neill CF; Harrap KR
    Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
    Farrell N; Kelland LR; Roberts JD; Van Beusichem M
    Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.